ELAB
Price
$2.17
Change
+$0.02 (+0.93%)
Updated
Jun 6 closing price
Capitalization
2.98M
REGN
Price
$493.22
Change
+$10.15 (+2.10%)
Updated
Jun 6 closing price
Capitalization
53.25B
54 days until earnings call
Interact to see
Advertisement

ELAB vs REGN

Header iconELAB vs REGN Comparison
Open Charts ELAB vs REGNBanner chart's image
PMGC Holdings
Price$2.17
Change+$0.02 (+0.93%)
Volume$18.78K
Capitalization2.98M
Regeneron Pharmaceuticals
Price$493.22
Change+$10.15 (+2.10%)
Volume$1.5M
Capitalization53.25B
ELAB vs REGN Comparison Chart
Loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAB vs. REGN commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a StrongBuy and REGN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ELAB: $2.17 vs. REGN: $493.22)
Brand notoriety: ELAB: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELAB: 3% vs. REGN: 108%
Market capitalization -- ELAB: $2.98M vs. REGN: $53.25B
ELAB [@Biotechnology] is valued at $2.98M. REGN’s [@Biotechnology] market capitalization is $53.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAB’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • ELAB’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than ELAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAB’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • ELAB’s TA Score: 4 bullish, 3 bearish.
  • REGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ELAB is a better buy in the short-term than REGN.

Price Growth

ELAB (@Biotechnology) experienced а +3.83% price change this week, while REGN (@Biotechnology) price change was +0.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

REGN is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($53.3B) has a higher market cap than ELAB($2.99M). REGN YTD gains are higher at: -30.568 vs. ELAB (-86.463). REGN has higher annual earnings (EBITDA): 5.53B vs. ELAB (-4.75M). ELAB has less debt than REGN: ELAB (103K) vs REGN (2.71B). REGN has higher revenues than ELAB: REGN (14.1B) vs ELAB (2.45M).
ELABREGNELAB / REGN
Capitalization2.99M53.3B0%
EBITDA-4.75M5.53B-0%
Gain YTD-86.463-30.568283%
P/E RatioN/A12.54-
Revenue2.45M14.1B0%
Total Cash6.43MN/A-
Total Debt103K2.71B0%
FUNDAMENTALS RATINGS
REGN: Fundamental Ratings
REGN
OUTLOOK RATING
1..100
4
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
53
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELABREGN
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
65%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
61%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 19 days ago
86%
Bullish Trend 19 days ago
61%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 3 days ago
55%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
58%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GHAYX41.05N/A
N/A
VanEck Global Resources Fund Y
GGFRX13.98N/A
N/A
Nationwide BNY Mellon Dyn US Core R
IVGSX22.80N/A
N/A
VY® Invesco Growth and Income S
FIQWX17.15N/A
N/A
Fidelity Advisor Strategic Div & Inc Z
MSHOX13.75N/A
N/A
Morgan Stanley Inst Permanence C

ELAB and

Correlation & Price change

A.I.dvisor tells us that ELAB and EPIX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ELAB and EPIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
+0.93%
EPIX - ELAB
30%
Poorly correlated
N/A
LXRX - ELAB
25%
Poorly correlated
+6.93%
EDSA - ELAB
22%
Poorly correlated
-6.63%
REGN - ELAB
20%
Poorly correlated
+2.10%
PRAX - ELAB
20%
Poorly correlated
+5.44%
More